uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.1465 | Q16 | What Small molecule therapies have been approved by the FDA to treat peripheral primitive neuroectodermal tumor? | There are no drug Small molecule therapies approved to treat peripheral primitive neuroectodermal tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peripheral primitive neuroectodermal tumor" OR LOWER(mesh_heading) = "peripheral primitive neuroectodermal tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.330 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abnormality of the skin? | There are no drug Small molecule therapies approved to treat Abnormality of the skin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormality of the skin" OR LOWER(mesh_heading) = "abnormality of the skin") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1353 | Q16 | What Small molecule therapies have been approved by the FDA to treat myeloproliferative disorder? | There are no drug Small molecule therapies approved to treat myeloproliferative disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myeloproliferative disorder" OR LOWER(mesh_heading) = "myeloproliferative disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.320 | Q16 | What Small molecule therapies have been approved by the FDA to treat AIDS? | There are 2 Small molecule therapy drugs that are approved to treat AIDS which are as follows: Megestrol Acetate and Crofelemer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aids" OR LOWER(mesh_heading) = "aids") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940515', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_940536', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_940557', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_940578', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_940599', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103255', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103259', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103263', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000001626', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103267', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103271', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}, {'UUID': 'DrugTargetsIndication121923_text_1103275', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000131620', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acquired Immunodeficiency Syndrome', 'efo_term': 'AIDS'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1348 | Q16 | What Small molecule therapies have been approved by the FDA to treat myelodysplastic syndrome? | There are 2 Small molecule therapy drugs that are approved to treat myelodysplastic syndrome which are as follows: Lenalidomide and Azacitidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myelodysplastic syndrome" OR LOWER(mesh_heading) = "myelodysplastic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1105734', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1105821', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1105908', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1105995', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106082', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106169', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106256', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106343', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106430', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106517', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106604', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106691', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106778', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106865', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1106952', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107039', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107126', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107213', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107300', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107387', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107474', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107561', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107648', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107735', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107822', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107909', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1107996', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108083', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108170', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108257', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108344', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108431', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108518', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108605', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108692', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108779', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108866', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1108953', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109040', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109127', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109214', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109301', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109388', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109475', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109562', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109649', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109736', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109823', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109910', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1109997', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110084', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110171', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110258', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110345', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110432', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110519', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110606', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110693', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110780', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110867', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1110954', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111041', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111128', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111215', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111302', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111389', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111476', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111563', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111650', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1111998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1112955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1113999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1114086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1114173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1114260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1114347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myelodysplastic Syndromes', 'efo_term': 'myelodysplastic syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1191 | Q16 | What Small molecule therapies have been approved by the FDA to treat infection? | There are 6 Small molecule therapy drugs that are approved to treat infection which are as follows: Betamethasone Dipropionate, Dexamethasone, Amantadine Hydrochloride, Doxycycline, Omeprazole, and Cobicistat. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "infection" OR LOWER(mesh_heading) = "infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220832', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220844', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220856', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220868', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220880', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220892', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_220904', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_226323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_226608', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_226893', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_227178', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_227463', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_227748', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_228033', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_228318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_228603', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_228888', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_229173', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_229458', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_229743', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_230028', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_230313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_230598', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_230883', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_231168', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_231453', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_231738', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_232023', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_232308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441019', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441033', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441047', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441061', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441075', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441089', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441103', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441117', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441131', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441145', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441159', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441173', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441187', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441201', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441215', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441229', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441243', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441257', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441271', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441285', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441299', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441313', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441327', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441341', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441355', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441369', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441383', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441397', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441411', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441425', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441439', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441453', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441467', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441481', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441495', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441509', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441523', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441537', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441551', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441565', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441579', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441593', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441607', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441621', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441635', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441649', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441663', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441677', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441691', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441705', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441719', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441733', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441747', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441761', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441775', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441789', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441803', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441817', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441831', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441845', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441859', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441873', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441887', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441901', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441915', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441929', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441943', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441957', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441971', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441985', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}, {'UUID': 'DrugTargetsIndication121923_text_441999', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1757 | Q16 | What Small molecule therapies have been approved by the FDA to treat voice disorders? | There are no drug Small molecule therapies approved to treat voice disorders. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "voice disorders" OR LOWER(mesh_heading) = "voice disorders") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.168 | Q16 | What Protein therapies have been approved by the FDA to treat hematopoietic and lymphoid cell neoplasm? | There are no drug Protein therapies approved to treat hematopoietic and lymphoid cell neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hematopoietic and lymphoid cell neoplasm" OR LOWER(mesh_heading) = "hematopoietic and lymphoid cell neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.13 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat primary hyperoxaluria type 1? | Lumasiran Sodium is the only Oligonucleotide therapy approved by the FDA to treat primary hyperoxaluria type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary hyperoxaluria type 1" OR LOWER(mesh_heading) = "primary hyperoxaluria type 1") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1041082', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041083', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041084', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041085', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041086', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041087', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041088', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041089', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041090', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041091', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041092', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041093', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000101323', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.172 | Q16 | What Protein therapies have been approved by the FDA to treat hepatocellular carcinoma? | There are no drug Protein therapies approved to treat hepatocellular carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatocellular carcinoma" OR LOWER(mesh_heading) = "hepatocellular carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.653 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tension-type headache? | There are no drug Small molecule therapies approved to treat Tension-type headache. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tension-type headache" OR LOWER(mesh_heading) = "tension-type headache") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.262 | Q16 | What Protein therapies have been approved by the FDA to treat post-operative sign or symptom? | There are no drug Protein therapies approved to treat post-operative sign or symptom. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "post-operative sign or symptom" OR LOWER(mesh_heading) = "post-operative sign or symptom") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1076 | Q16 | What Small molecule therapies have been approved by the FDA to treat filarial elephantiasis? | There are no drug Small molecule therapies approved to treat filarial elephantiasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "filarial elephantiasis" OR LOWER(mesh_heading) = "filarial elephantiasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1235 | Q16 | What Small molecule therapies have been approved by the FDA to treat kidney neoplasm? | There are no drug Small molecule therapies approved to treat kidney neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kidney neoplasm" OR LOWER(mesh_heading) = "kidney neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.676 | Q16 | What Small molecule therapies have been approved by the FDA to treat Vibrio infectious disease? | Doxycycline is the only Small molecule therapy approved by the FDA to treat Vibrio infectious disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vibrio infectious disease" OR LOWER(mesh_heading) = "vibrio infectious disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1037852', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1037927', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038002', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038077', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038152', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038227', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038302', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038377', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038452', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038527', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038602', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038677', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038752', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038827', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038902', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1038977', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039052', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039127', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039202', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039277', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039352', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039427', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039502', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039577', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039652', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039727', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039802', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039877', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1039952', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040027', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040102', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040177', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040252', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040327', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040402', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040477', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040552', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040627', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040702', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040777', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040852', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1040927', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1041002', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}, {'UUID': 'DrugTargetsIndication121923_text_1041077', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.260 | Q16 | What Protein therapies have been approved by the FDA to treat pleural effusion? | There are no drug Protein therapies approved to treat pleural effusion. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pleural effusion" OR LOWER(mesh_heading) = "pleural effusion") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1571 | Q16 | What Small molecule therapies have been approved by the FDA to treat renal cell carcinoma? | There are 10 Small molecule therapy drugs that are approved to treat renal cell carcinoma which are as follows: Pazopanib Hydrochloride, Cabozantinib S-Malate, Tivozanib Hydrochloride, Sorafenib Tosylate, Sorafenib, Axitinib, Lenvatinib Mesylate, Everolimus, Temsirolimus, and Belzutifan. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal cell carcinoma" OR LOWER(mesh_heading) = "renal cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_667825', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667853', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667881', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667909', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667937', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667965', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667993', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668021', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668049', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668077', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668105', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668133', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668161', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668189', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668217', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668245', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668273', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668301', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668329', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668357', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668385', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668413', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669559', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669582', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669605', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669628', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669651', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669674', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669697', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669720', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669743', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669766', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669789', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669812', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669835', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669858', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669881', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669904', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669927', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669950', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669973', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669996', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670019', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670042', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670065', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670088', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670111', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670134', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670157', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670180', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670203', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670226', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670249', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670272', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670295', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670318', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670341', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670364', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670387', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670410', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670433', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670456', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670479', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670502', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670525', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670548', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670571', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670594', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670617', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670640', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670663', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670686', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670709', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670732', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670755', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670778', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670801', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670824', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670847', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670870', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670893', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670916', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670939', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670962', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670985', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671008', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671031', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671054', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671077', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671100', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671123', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671146', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671169', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671192', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671215', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671238', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671261', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671284', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671307', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671330', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.139 | Q16 | What Protein therapies have been approved by the FDA to treat cutaneous melanoma? | There are no drug Protein therapies approved to treat cutaneous melanoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cutaneous melanoma" OR LOWER(mesh_heading) = "cutaneous melanoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.553 | Q16 | What Small molecule therapies have been approved by the FDA to treat Muscle spasm? | There are 4 Small molecule therapy drugs that are approved to treat Muscle spasm which are as follows: Cyclobenzaprine Hydrochloride, Lidocaine, Aspirin, and Capsaicin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "muscle spasm" OR LOWER(mesh_heading) = "muscle spasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151248', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151254', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151260', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151266', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151272', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151278', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151284', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151290', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151296', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151302', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151308', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151314', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151320', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151326', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151332', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151338', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151344', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151350', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151356', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151362', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151368', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151374', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151380', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151386', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151392', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151398', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151404', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151410', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151416', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151422', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151428', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_151434', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_637777', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_637892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_638927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639502', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639617', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639732', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639847', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_639962', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640077', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640192', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640307', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640422', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640537', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640652', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640767', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640882', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_640997', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641112', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641227', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641342', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641457', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641572', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641687', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641802', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_641917', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642032', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642147', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642262', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642377', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642492', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642607', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642722', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642837', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_642952', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643067', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643182', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643297', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643412', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643527', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643642', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643757', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643872', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_643987', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_644102', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_644217', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_644332', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_644447', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_644562', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_833642', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_833799', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_833956', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_834113', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_834270', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_834427', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_834584', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}, {'UUID': 'DrugTargetsIndication121923_text_834741', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1230 | Q16 | What Small molecule therapies have been approved by the FDA to treat keratosis? | There are 3 Small molecule therapy drugs that are approved to treat keratosis which are as follows: Diclofenac, Fluorouracil, and Imiquimod. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "keratosis" OR LOWER(mesh_heading) = "keratosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_836983', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837013', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837043', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837073', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837103', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837133', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837163', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837193', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837223', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837253', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837283', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837313', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837343', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837373', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837403', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837433', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837463', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837493', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837523', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837553', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837583', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837613', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837643', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837673', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837703', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837733', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837763', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837793', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837823', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837853', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837883', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837913', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837943', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837973', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_838003', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_838033', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919467', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919516', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919569', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919622', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919675', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919728', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919781', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919834', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919887', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919940', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919993', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920046', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920099', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920152', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920205', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920258', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920311', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1742 | Q16 | What Small molecule therapies have been approved by the FDA to treat varicose ulcer? | There are no drug Small molecule therapies approved to treat varicose ulcer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "varicose ulcer" OR LOWER(mesh_heading) = "varicose ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1096 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastric ulcer? | There are 6 Small molecule therapy drugs that are approved to treat gastric ulcer which are as follows: Naproxen, Esomeprazole Magnesium, Omeprazole, Lansoprazole, Dexlansoprazole, and Famotidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastric ulcer" OR LOWER(mesh_heading) = "gastric ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838342', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838383', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838424', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838465', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838506', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838547', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838588', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838629', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838670', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838711', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838752', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838793', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838834', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838875', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838916', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838957', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_838998', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839039', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839080', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839121', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839162', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839203', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839244', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839285', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839326', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839367', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839408', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839449', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839490', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839531', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839572', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839613', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839654', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_839695', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097864', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097876', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097888', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097900', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1097969', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098039', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098109', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098179', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098249', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098319', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098345', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098369', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098393', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098417', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098425', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098433', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098441', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098449', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098457', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098465', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098473', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098481', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098489', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098497', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098505', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098513', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098521', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098529', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098537', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098545', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098553', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098561', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098569', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098577', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098585', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098593', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098601', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098609', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098617', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098625', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098633', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098641', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098649', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098657', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098665', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098673', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098681', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098689', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098697', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098705', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098713', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098721', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098729', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098737', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098745', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098753', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098761', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098769', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098777', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098785', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098793', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098801', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098809', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098817', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098825', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098833', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1725 | Q16 | What Small molecule therapies have been approved by the FDA to treat ureter cancer? | There are no drug Small molecule therapies approved to treat ureter cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ureter cancer" OR LOWER(mesh_heading) = "ureter cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.562 | Q16 | What Small molecule therapies have been approved by the FDA to treat Nasal polyposis? | There are 2 Small molecule therapy drugs that are approved to treat Nasal polyposis which are as follows: Fluticasone Propionate and Mometasone Furoate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nasal polyposis" OR LOWER(mesh_heading) = "nasal polyposis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232392', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232419', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232446', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232473', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232500', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232527', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232554', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232581', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232608', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232635', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232662', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232689', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232716', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232743', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232770', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232797', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232824', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232851', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232878', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232905', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232932', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232959', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_232986', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233013', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233040', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233067', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233094', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233121', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233148', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233175', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233202', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233229', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233256', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233283', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233310', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233337', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233364', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233391', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233418', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233445', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233472', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233499', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233526', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233553', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233580', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233607', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233634', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233661', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233688', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233715', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233742', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233769', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233796', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233823', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233850', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233877', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233904', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233931', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233958', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_233985', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234012', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234039', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234066', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234093', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234120', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234147', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234174', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234201', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234228', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234255', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234282', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234309', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234336', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234363', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234390', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234417', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234444', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234471', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234498', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234525', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234552', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234579', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234606', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234633', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234660', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234687', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234714', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234741', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234768', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234795', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234822', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234849', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234876', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234903', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234930', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234957', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_234984', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_235011', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_235038', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}, {'UUID': 'DrugTargetsIndication121923_text_235065', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.140 | Q16 | What Protein therapies have been approved by the FDA to treat deep vein thrombosis? | There are no drug Protein therapies approved to treat deep vein thrombosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "deep vein thrombosis" OR LOWER(mesh_heading) = "deep vein thrombosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1530 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary systemic amyloidosis? | There are no drug Small molecule therapies approved to treat primary systemic amyloidosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary systemic amyloidosis" OR LOWER(mesh_heading) = "primary systemic amyloidosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.535 | Q16 | What Small molecule therapies have been approved by the FDA to treat Lyme disease? | There are no drug Small molecule therapies approved to treat Lyme disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lyme disease" OR LOWER(mesh_heading) = "lyme disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.226 | Q16 | What Protein therapies have been approved by the FDA to treat mycosis fungoides? | There are no drug Protein therapies approved to treat mycosis fungoides. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mycosis fungoides" OR LOWER(mesh_heading) = "mycosis fungoides") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.729 | Q16 | What Small molecule therapies have been approved by the FDA to treat alcohol abuse? | Naltrexone is the only Small molecule therapy approved by the FDA to treat alcohol abuse. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alcohol abuse" OR LOWER(mesh_heading) = "alcohol abuse") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_785064', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}, {'UUID': 'DrugTargetsIndication121923_text_785109', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}, {'UUID': 'DrugTargetsIndication121923_text_785154', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}, {'UUID': 'DrugTargetsIndication121923_text_785199', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}, {'UUID': 'DrugTargetsIndication121923_text_785244', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}, {'UUID': 'DrugTargetsIndication121923_text_785289', 'drugName': 'Naltrexone', 'tradeNames_list': "['Celupan', 'Trexal', 'Trexan', 'Vivitrol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol abuse'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.939 | Q16 | What Small molecule therapies have been approved by the FDA to treat colon adenocarcinoma? | There are no drug Small molecule therapies approved to treat colon adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colon adenocarcinoma" OR LOWER(mesh_heading) = "colon adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.412 | Q16 | What Small molecule therapies have been approved by the FDA to treat Disseminated intravascular coagulation? | There are no drug Small molecule therapies approved to treat Disseminated intravascular coagulation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "disseminated intravascular coagulation" OR LOWER(mesh_heading) = "disseminated intravascular coagulation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.327 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abnormality of cardiovascular system morphology? | There are no drug Small molecule therapies approved to treat Abnormality of cardiovascular system morphology. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormality of cardiovascular system morphology" OR LOWER(mesh_heading) = "abnormality of cardiovascular system morphology") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.929 | Q16 | What Small molecule therapies have been approved by the FDA to treat classic Hodgkin lymphoma? | There are no drug Small molecule therapies approved to treat classic Hodgkin lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "classic hodgkin lymphoma" OR LOWER(mesh_heading) = "classic hodgkin lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.301 | Q16 | What Protein therapies have been approved by the FDA to treat sudden cardiac arrest? | There are no drug Protein therapies approved to treat sudden cardiac arrest. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sudden cardiac arrest" OR LOWER(mesh_heading) = "sudden cardiac arrest") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1116 | Q16 | What Small molecule therapies have been approved by the FDA to treat grade III meningioma? | There are no drug Small molecule therapies approved to treat grade III meningioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "grade iii meningioma" OR LOWER(mesh_heading) = "grade iii meningioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.996 | Q16 | What Small molecule therapies have been approved by the FDA to treat digestive system cancer? | There are no drug Small molecule therapies approved to treat digestive system cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "digestive system cancer" OR LOWER(mesh_heading) = "digestive system cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.906 | Q16 | What Small molecule therapies have been approved by the FDA to treat choroid plexus neoplasm? | There are no drug Small molecule therapies approved to treat choroid plexus neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "choroid plexus neoplasm" OR LOWER(mesh_heading) = "choroid plexus neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1634 | Q16 | What Small molecule therapies have been approved by the FDA to treat small cell carcinoma? | Topotecan Hydrochloride is the only Small molecule therapy approved by the FDA to treat small cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "small cell carcinoma" OR LOWER(mesh_heading) = "small cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193576', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1193648', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.720 | Q16 | What Small molecule therapies have been approved by the FDA to treat adrenal gland pheochromocytoma? | Phentolamine Mesylate is the only Small molecule therapy approved by the FDA to treat adrenal gland pheochromocytoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adrenal gland pheochromocytoma" OR LOWER(mesh_heading) = "adrenal gland pheochromocytoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418208', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418211', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418214', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418217', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418220', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418223', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418226', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418229', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418232', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418235', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418238', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418241', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418244', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418247', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418250', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418253', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418256', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_418259', 'drugName': 'Phentolamine Mesylate', 'tradeNames_list': "['Oraverse', 'Phentolamine mesylate', 'Regitine', 'Rogitine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pheochromocytoma', 'efo_term': 'adrenal gland pheochromocytoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.194 | Q16 | What Protein therapies have been approved by the FDA to treat keratoconjunctivitis? | Cyclosporine is the only Protein therapy approved by the FDA to treat keratoconjunctivitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "keratoconjunctivitis" OR LOWER(mesh_heading) = "keratoconjunctivitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100649', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1100776', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1100903', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101030', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101157', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101284', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101411', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101538', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101665', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101792', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1101919', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102046', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102173', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102300', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102427', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102554', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102681', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102808', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1102935', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_1103062', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratoconjunctivitis', 'efo_term': 'keratoconjunctivitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.444 | Q16 | What Small molecule therapies have been approved by the FDA to treat Fish-eye disease? | There are no drug Small molecule therapies approved to treat Fish-eye disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fish-eye disease" OR LOWER(mesh_heading) = "fish-eye disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.577 | Q16 | What Small molecule therapies have been approved by the FDA to treat Oral ulcer? | Apremilast is the only Small molecule therapy approved by the FDA to treat Oral ulcer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oral ulcer" OR LOWER(mesh_heading) = "oral ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696791', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696819', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696847', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696875', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696903', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696931', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696959', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_696987', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697015', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697043', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697071', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697099', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697127', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697155', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697183', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697211', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697239', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697267', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697295', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697323', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697351', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697379', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697407', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697435', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697463', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697491', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697519', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697547', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697575', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697603', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697631', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697659', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697687', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697715', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697743', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697771', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697799', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697827', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697855', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697883', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697911', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697939', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697967', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_697995', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698023', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698051', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698079', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698107', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698135', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698163', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698191', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698219', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698247', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698275', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698303', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698331', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698359', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698387', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698415', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698443', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698471', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698499', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698527', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698555', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698583', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698611', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698639', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698667', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698695', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698723', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698751', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698779', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698807', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698835', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698863', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698891', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698919', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698947', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_698975', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699003', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699031', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699059', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699087', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699115', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699143', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699171', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699199', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699227', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699255', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699283', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065989', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699311', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699339', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699367', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699395', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699423', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699451', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699479', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699507', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699535', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_699563', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113448', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.507 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hypogonadotropic hypogonadism? | There are 2 Small molecule therapy drugs that are approved to treat Hypogonadotropic hypogonadism which are as follows: Testosterone Enanthate and Testosterone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypogonadotropic hypogonadism" OR LOWER(mesh_heading) = "hypogonadotropic hypogonadism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921815', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921824', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921833', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921842', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921976', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_921989', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922002', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922015', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922028', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922041', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922054', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922067', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922080', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922093', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922106', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922119', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922132', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922145', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922158', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922171', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922184', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922197', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922210', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922223', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922236', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922249', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922262', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922275', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922288', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922301', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922314', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922327', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922340', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922353', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922366', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922379', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922392', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922405', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922418', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922431', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922444', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922457', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922470', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922483', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922496', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922524', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922528', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922560', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922564', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism'}, {'UUID': 'DrugTargetsIndication121923_text_922596', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.609 | Q16 | What Small molecule therapies have been approved by the FDA to treat Recurrent thrombophlebitis? | There are 10 Small molecule therapy drugs that are approved to treat Recurrent thrombophlebitis which are as follows: Treprostinil, Selexipag, Rivaroxaban, Apixaban, Betrixaban, Aspirin, Ticagrelor, Cangrelor Tetrasodium, Dabigatran Etexilate, and Argatroban. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "recurrent thrombophlebitis" OR LOWER(mesh_heading) = "recurrent thrombophlebitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244448', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244465', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244482', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244499', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244516', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244533', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244550', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244567', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244584', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244601', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244618', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244635', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244652', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244669', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244686', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244703', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244720', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244737', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244754', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244771', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244788', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244805', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244822', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244839', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244856', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244873', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244890', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244907', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244924', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244941', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244958', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244975', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_244992', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245009', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245026', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245043', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245060', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245077', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245094', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245111', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245128', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245145', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245162', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245179', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245196', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245213', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245230', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245247', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245264', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245281', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245298', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245315', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245332', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245349', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245366', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245383', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245400', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245417', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245434', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245451', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245468', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245485', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245502', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245519', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245536', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245553', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245570', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245587', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245604', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245621', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245638', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245655', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245672', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245689', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245706', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245723', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245740', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245757', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245774', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245791', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245808', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245825', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245842', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245859', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245876', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245893', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245910', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245927', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245944', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245961', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_245978', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246123', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246127', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246131', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246135', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246139', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246143', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246147', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246151', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}, {'UUID': 'DrugTargetsIndication121923_text_246155', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1679 | Q16 | What Small molecule therapies have been approved by the FDA to treat systemic scleroderma? | Nintedanib Esylate is the only Small molecule therapy approved by the FDA to treat systemic scleroderma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systemic scleroderma" OR LOWER(mesh_heading) = "systemic scleroderma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_678467', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678469', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678471', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678473', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678475', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678477', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678479', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678481', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678483', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678485', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678487', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678489', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678491', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678493', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678495', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678497', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678499', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678501', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678503', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678505', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678507', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678509', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678511', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678513', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678515', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678517', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678519', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678521', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678523', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678525', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678527', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678529', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678531', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678533', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678535', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678537', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678539', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678541', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678543', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678545', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678547', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678549', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678551', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678553', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678555', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678557', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678559', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678561', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678563', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678565', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678567', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678569', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678571', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678573', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678575', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678577', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678579', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678581', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678583', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678585', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678587', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678589', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678591', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678593', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678595', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678597', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678599', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678601', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678603', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678605', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678607', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678609', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678611', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678613', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678615', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678617', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678619', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678621', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678623', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678625', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678627', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678629', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678631', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678633', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678635', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678637', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678639', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678641', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678643', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}, {'UUID': 'DrugTargetsIndication121923_text_678645', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Scleroderma, Systemic', 'efo_term': 'systemic scleroderma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1573 | Q16 | What Small molecule therapies have been approved by the FDA to treat reproductive system disease? | There are no drug Small molecule therapies approved to treat reproductive system disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "reproductive system disease" OR LOWER(mesh_heading) = "reproductive system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.4 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat amyloidosis? | There are 2 Oligonucleotide therapy drugs that are approved to treat amyloidosis which are as follows: Inotersen Sodium and Patisiran Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amyloidosis" OR LOWER(mesh_heading) = "amyloidosis") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097644', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097647', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097650', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097653', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097656', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097659', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097686', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097689', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097692', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097695', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097698', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097701', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097704', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097707', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097710', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097713', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097716', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097719', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097722', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097725', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097728', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097731', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1325 | Q16 | What Small molecule therapies have been approved by the FDA to treat mitral valve stenosis? | There are no drug Small molecule therapies approved to treat mitral valve stenosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mitral valve stenosis" OR LOWER(mesh_heading) = "mitral valve stenosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1320 | Q16 | What Small molecule therapies have been approved by the FDA to treat microscopic colitis? | There are no drug Small molecule therapies approved to treat microscopic colitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "microscopic colitis" OR LOWER(mesh_heading) = "microscopic colitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.471 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hallucinations? | Pimavanserin Tartrate is the only Small molecule therapy approved by the FDA to treat Hallucinations. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hallucinations" OR LOWER(mesh_heading) = "hallucinations") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205091', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205096', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205101', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205106', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205111', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205116', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205121', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205126', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205131', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205136', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205141', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205146', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205151', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205156', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205161', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205166', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205171', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205176', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205181', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205186', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205191', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205196', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205201', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205206', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205211', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205216', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205221', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205226', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205231', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205236', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205241', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}, {'UUID': 'DrugTargetsIndication121923_text_205246', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'drugType': 'Small molecule', 'actionType': 'inverse agonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hallucinations', 'efo_term': 'Hallucinations'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.323 | Q16 | What Small molecule therapies have been approved by the FDA to treat Abdominal Aortic Aneurysm? | There are no drug Small molecule therapies approved to treat Abdominal Aortic Aneurysm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abdominal aortic aneurysm" OR LOWER(mesh_heading) = "abdominal aortic aneurysm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.6 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat cardiovascular disease? | Mipomersen Sodium is the only Oligonucleotide therapy approved by the FDA to treat cardiovascular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiovascular disease" OR LOWER(mesh_heading) = "cardiovascular disease") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191788', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease'}, {'UUID': 'DrugTargetsIndication121923_text_1191791', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease'}, {'UUID': 'DrugTargetsIndication121923_text_1191794', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.224 | Q16 | What Protein therapies have been approved by the FDA to treat multiple myeloma? | Carfilzomib is the only Protein therapy approved by the FDA to treat multiple myeloma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "multiple myeloma" OR LOWER(mesh_heading) = "multiple myeloma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_267903', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_267930', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_267957', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_267984', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268011', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268038', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268065', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268092', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268119', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268146', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268173', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268200', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268227', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268254', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268281', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268308', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268335', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268362', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268389', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268416', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268443', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268470', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268497', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268524', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268551', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268578', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268605', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268632', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268659', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268686', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268713', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268740', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268767', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268794', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268821', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268848', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268875', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268902', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268929', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268956', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_268983', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269010', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269037', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269064', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269091', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269118', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269145', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269172', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269199', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269226', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269253', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269280', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269307', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269334', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269361', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269388', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269415', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269442', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269469', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269496', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269523', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269550', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269577', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269604', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269631', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269658', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269685', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269712', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269739', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269766', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269793', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269820', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269847', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269874', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269901', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269928', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269955', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_269982', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270009', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270036', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270063', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270090', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270117', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270144', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270171', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270198', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270225', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270252', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270279', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270306', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270333', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270360', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270387', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270414', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270441', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270468', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270495', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270522', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270549', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}, {'UUID': 'DrugTargetsIndication121923_text_270576', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.551 | Q16 | What Small molecule therapies have been approved by the FDA to treat Morton Neuroma? | There are no drug Small molecule therapies approved to treat Morton Neuroma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "morton neuroma" OR LOWER(mesh_heading) = "morton neuroma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1014 | Q16 | What Small molecule therapies have been approved by the FDA to treat embryonal neoplasm? | There are no drug Small molecule therapies approved to treat embryonal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "embryonal neoplasm" OR LOWER(mesh_heading) = "embryonal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.40 | Q16 | What Protein therapies have been approved by the FDA to treat Epiphora? | There are no drug Protein therapies approved to treat Epiphora. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epiphora" OR LOWER(mesh_heading) = "epiphora") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.546 | Q16 | What Small molecule therapies have been approved by the FDA to treat Menorrhagia? | There are 2 Small molecule therapy drugs that are approved to treat Menorrhagia which are as follows: Levonorgestrel and Tranexamic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "menorrhagia" OR LOWER(mesh_heading) = "menorrhagia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940165', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940184', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940203', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940222', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940241', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940260', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940279', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940298', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940317', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940336', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940355', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940374', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940393', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940412', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940431', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_940450', 'drugName': 'Levonorgestrel', 'tradeNames_list': "['Athentia next', 'Emerres', 'Emerres una', 'Ezinelle', 'Fallback soloHer style', 'Isteranda', 'Jadelle', 'Jaydess', 'Kyleena', 'LevonelleLevonelle one step', 'Levonelle-2', 'Levonorgestrel', 'Levosert', 'LilettaMicroval', 'Mirena', 'Norgeston', 'Norplant', 'Norplant IiNorplant System', 'Opcicon one-step', 'Ovrette', 'Plan B', 'Plan b one-stepPostinor-2', 'Skyla', 'Upostelle']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993327', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993385', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993443', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993501', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993559', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993617', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993675', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}, {'UUID': 'DrugTargetsIndication121923_text_993733', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.244 | Q16 | What Protein therapies have been approved by the FDA to treat opioid dependence? | There are no drug Protein therapies approved to treat opioid dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "opioid dependence" OR LOWER(mesh_heading) = "opioid dependence") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1643 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal cord disease? | There are 2 Small molecule therapy drugs that are approved to treat spinal cord disease which are as follows: Cyclobenzaprine Hydrochloride and Baclofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal cord disease" OR LOWER(mesh_heading) = "spinal cord disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151249', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151255', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151261', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151267', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151273', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151279', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151285', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151291', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151297', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151303', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151309', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151315', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151321', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151327', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151333', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151339', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151345', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151351', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151357', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151363', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151369', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151375', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151381', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151387', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151393', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151399', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151405', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151411', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151417', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151423', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151429', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_151435', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193120', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193145', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193170', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193195', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193220', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000204681', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193245', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193270', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193295', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193320', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}, {'UUID': 'DrugTargetsIndication121923_text_1193345', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000136928', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2', 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.137 | Q16 | What Protein therapies have been approved by the FDA to treat constipation disorder? | Linaclotide is the only Protein therapy approved by the FDA to treat constipation disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "constipation disorder" OR LOWER(mesh_heading) = "constipation disorder") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092089', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092093', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092097', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092101', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092105', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092109', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092113', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092117', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092121', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092125', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092129', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092133', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092137', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092141', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092145', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092149', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092153', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092157', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092161', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092165', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092169', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092173', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092177', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092181', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092185', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092189', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092193', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092197', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092201', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092205', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092209', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092213', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092217', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092221', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092225', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1545 | Q16 | What Small molecule therapies have been approved by the FDA to treat ptosis? | Oxymetazoline Hydrochloride is the only Small molecule therapy approved by the FDA to treat ptosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ptosis" OR LOWER(mesh_heading) = "ptosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417195', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417205', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417215', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417225', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417235', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417245', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417255', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417265', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417275', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417285', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417295', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417305', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417315', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417325', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417335', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417345', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417355', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417365', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417375', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417385', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417395', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417405', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417415', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417425', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417435', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417445', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417455', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417465', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417475', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417485', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417495', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417505', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417515', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417525', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417535', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417545', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417555', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417565', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417575', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417585', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417595', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417605', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417615', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417625', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417635', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417645', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417655', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417665', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417675', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417685', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417695', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417705', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417715', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417725', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417735', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417745', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417755', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417765', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417775', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417785', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417795', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417805', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417815', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417825', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417835', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417845', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417855', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417865', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417875', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417885', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417895', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417905', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417915', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417925', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417935', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417945', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417955', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417965', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417975', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417985', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_417995', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418005', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418015', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418025', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418035', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418045', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418055', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418065', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418075', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418085', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418095', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418105', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418115', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418125', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418135', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418145', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418155', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418165', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418175', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}, {'UUID': 'DrugTargetsIndication121923_text_418185', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Blepharoptosis', 'efo_term': 'ptosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1387 | Q16 | What Small molecule therapies have been approved by the FDA to treat non-Hodgkins lymphoma? | There are 3 Small molecule therapy drugs that are approved to treat non-Hodgkins lymphoma which are as follows: Idelalisib, Methotrexate, and Plerixafor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-hodgkins lymphoma" OR LOWER(mesh_heading) = "non-hodgkins lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858398', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858417', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858436', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858455', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858474', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858493', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858512', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858531', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858550', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858569', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858588', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858607', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858626', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858645', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858664', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858683', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858702', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858721', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1056789', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1056950', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057111', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057272', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057433', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057594', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057755', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1057916', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058077', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058238', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058399', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058560', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058721', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1058882', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059043', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059204', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059365', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059526', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059687', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1059848', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060009', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060170', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060331', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060492', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060653', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060814', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1060975', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061136', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061297', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061458', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061619', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061780', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1061941', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062102', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062263', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062424', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062585', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062746', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1062907', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063068', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063229', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063390', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063551', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063712', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1063873', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064034', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064195', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064356', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064517', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064678', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1064839', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065000', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065161', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065322', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065483', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065644', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065805', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1065966', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066127', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066288', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066449', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066610', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066771', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1066932', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067093', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067254', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067415', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067576', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067737', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1067898', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068059', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068220', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068381', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068542', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068703', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1068864', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069025', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069186', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069347', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069508', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069669', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1069830', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'non-Hodgkins lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.816 | Q16 | What Small molecule therapies have been approved by the FDA to treat beta-thalassemia major? | There are no drug Small molecule therapies approved to treat beta-thalassemia major. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "beta-thalassemia major" OR LOWER(mesh_heading) = "beta-thalassemia major") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.449 | Q16 | What Small molecule therapies have been approved by the FDA to treat Gaucher disease type 1? | There are no drug Small molecule therapies approved to treat Gaucher disease type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gaucher disease type 1" OR LOWER(mesh_heading) = "gaucher disease type 1") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.912 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic hepatitis B virus infection? | There are no drug Small molecule therapies approved to treat chronic hepatitis B virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic hepatitis b virus infection" OR LOWER(mesh_heading) = "chronic hepatitis b virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1244 | Q16 | What Small molecule therapies have been approved by the FDA to treat left ventricular hypertrophy? | There are no drug Small molecule therapies approved to treat left ventricular hypertrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "left ventricular hypertrophy" OR LOWER(mesh_heading) = "left ventricular hypertrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1565 | Q16 | What Small molecule therapies have been approved by the FDA to treat reflex sympathetic dystrophy? | There are no drug Small molecule therapies approved to treat reflex sympathetic dystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "reflex sympathetic dystrophy" OR LOWER(mesh_heading) = "reflex sympathetic dystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1605 | Q16 | What Small molecule therapies have been approved by the FDA to treat scleroderma? | There are no drug Small molecule therapies approved to treat scleroderma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "scleroderma" OR LOWER(mesh_heading) = "scleroderma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.585 | Q16 | What Small molecule therapies have been approved by the FDA to treat Patent ductus arteriosus? | There are 3 Small molecule therapy drugs that are approved to treat Patent ductus arteriosus which are as follows: Indomethacin, Ibuprofen, and Ibuprofen Lysine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "patent ductus arteriosus" OR LOWER(mesh_heading) = "patent ductus arteriosus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828197', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828231', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828265', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828299', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828333', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828367', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828401', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828435', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828469', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828503', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828537', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_828571', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_839759', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_839838', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_839917', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_839996', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840075', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840154', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840233', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840312', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840391', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840470', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840549', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840628', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840707', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840786', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840865', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_840944', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841023', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841102', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841181', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841260', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841339', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841418', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841497', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841576', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841655', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_841734', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_842285', 'drugName': 'Ibuprofen Lysine', 'tradeNames_list': "['Feminax express', 'Ibuprofen lysine', 'Neoprofen', 'Nurofen advanceNurofen max strgth mig pain', 'Nurofen migraine painNurofen tension headache']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}, {'UUID': 'DrugTargetsIndication121923_text_842286', 'drugName': 'Ibuprofen Lysine', 'tradeNames_list': "['Feminax express', 'Ibuprofen lysine', 'Neoprofen', 'Nurofen advanceNurofen max strgth mig pain', 'Nurofen migraine painNurofen tension headache']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1554 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary venoocclusive disease? | There are no drug Small molecule therapies approved to treat pulmonary venoocclusive disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary venoocclusive disease" OR LOWER(mesh_heading) = "pulmonary venoocclusive disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1733 | Q16 | What Small molecule therapies have been approved by the FDA to treat urothelial carcinoma? | Erdafitinib is the only Small molecule therapy approved by the FDA to treat urothelial carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urothelial carcinoma" OR LOWER(mesh_heading) = "urothelial carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707095', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707096', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707111', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707112', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707127', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707128', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707143', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707144', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707159', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707160', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707175', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707176', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707191', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707192', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707207', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707208', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707223', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707224', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707239', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707240', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707255', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707256', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707271', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707272', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707287', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707288', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707303', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707304', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707319', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707320', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707335', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707336', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707351', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707352', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707367', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707368', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707383', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707384', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707399', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707400', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707415', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707416', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707431', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707432', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707447', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707448', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707463', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707464', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707479', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707480', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707495', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707496', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707511', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707512', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707527', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707528', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707543', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707544', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707559', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707560', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707575', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707576', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707591', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707592', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707607', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707608', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707623', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707624', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707639', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707640', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707655', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707656', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707671', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707672', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707687', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707688', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707703', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707704', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707719', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707720', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707735', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707736', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707751', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707752', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707767', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707768', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707783', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707784', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707799', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707800', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707815', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707816', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707831', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707832', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707847', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707848', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707863', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707864', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707879', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_707880', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Transitional Cell', 'efo_term': 'urothelial carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.665 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tremor? | There are no drug Small molecule therapies approved to treat Tremor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tremor" OR LOWER(mesh_heading) = "tremor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.440 | Q16 | What Small molecule therapies have been approved by the FDA to treat Familial dysautonomia? | There are no drug Small molecule therapies approved to treat Familial dysautonomia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial dysautonomia" OR LOWER(mesh_heading) = "familial dysautonomia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1632 | Q16 | What Small molecule therapies have been approved by the FDA to treat sleep apnea? | There are no drug Small molecule therapies approved to treat sleep apnea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sleep apnea" OR LOWER(mesh_heading) = "sleep apnea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.379 | Q16 | What Small molecule therapies have been approved by the FDA to treat Central Nervous System Neoplasm? | There are no drug Small molecule therapies approved to treat Central Nervous System Neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "central nervous system neoplasm" OR LOWER(mesh_heading) = "central nervous system neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1296 | Q16 | What Small molecule therapies have been approved by the FDA to treat mature T-cell and NK-cell non-Hodgkin lymphoma? | There are 2 Small molecule therapy drugs that are approved to treat mature T-cell and NK-cell non-Hodgkin lymphoma which are as follows: Pralatrexate and Belinostat. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mature t-cell and nk-cell non-hodgkin lymphoma" OR LOWER(mesh_heading) = "mature t-cell and nk-cell non-hodgkin lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072440', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072459', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072478', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072497', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072516', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072535', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079816', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116478', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079852', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116478', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079888', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171720', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079924', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171720', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079960', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000094631', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079996', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000094631', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080032', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196591', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080068', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196591', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080104', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108840', 'approvedSymbol': 'HDAC5', 'approvedName': 'histone deacetylase 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080140', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108840', 'approvedSymbol': 'HDAC5', 'approvedName': 'histone deacetylase 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080176', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000061273', 'approvedSymbol': 'HDAC7', 'approvedName': 'histone deacetylase 7', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080212', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000061273', 'approvedSymbol': 'HDAC7', 'approvedName': 'histone deacetylase 7', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080248', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000147099', 'approvedSymbol': 'HDAC8', 'approvedName': 'histone deacetylase 8', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080284', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000147099', 'approvedSymbol': 'HDAC8', 'approvedName': 'histone deacetylase 8', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080320', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163517', 'approvedSymbol': 'HDAC11', 'approvedName': 'histone deacetylase 11', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080356', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163517', 'approvedSymbol': 'HDAC11', 'approvedName': 'histone deacetylase 11', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080392', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068024', 'approvedSymbol': 'HDAC4', 'approvedName': 'histone deacetylase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080428', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068024', 'approvedSymbol': 'HDAC4', 'approvedName': 'histone deacetylase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080464', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000048052', 'approvedSymbol': 'HDAC9', 'approvedName': 'histone deacetylase 9', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080500', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000048052', 'approvedSymbol': 'HDAC9', 'approvedName': 'histone deacetylase 9', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080536', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100429', 'approvedSymbol': 'HDAC10', 'approvedName': 'histone deacetylase 10', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080572', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100429', 'approvedSymbol': 'HDAC10', 'approvedName': 'histone deacetylase 10', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.316 | Q16 | What Protein therapies have been approved by the FDA to treat uveitis? | There are no drug Protein therapies approved to treat uveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uveitis" OR LOWER(mesh_heading) = "uveitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.446 | Q16 | What Small molecule therapies have been approved by the FDA to treat Focal-onset seizure? | There are 3 Small molecule therapy drugs that are approved to treat Focal-onset seizure which are as follows: Cenobamate, Pregabalin, and Levetiracetam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "focal-onset seizure" OR LOWER(mesh_heading) = "focal-onset seizure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_456000', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456005', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456010', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456015', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456020', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456025', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456030', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456035', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456040', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456045', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456050', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456055', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456060', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456065', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456070', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456075', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456080', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456085', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456090', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456095', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456100', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456105', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456110', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456115', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456120', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456125', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456130', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456135', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456140', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456145', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456150', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456155', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456160', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456165', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456170', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456175', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456180', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456185', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456190', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456195', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456200', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456205', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456210', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456215', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456220', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456225', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456230', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456235', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456240', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456245', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456250', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456255', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456260', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456265', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456270', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456275', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456280', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456285', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456290', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456295', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456300', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456305', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456310', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456315', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456320', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456325', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000022355', 'approvedSymbol': 'GABRA1', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha1', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456330', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456335', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456340', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456345', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456350', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456355', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000145864', 'approvedSymbol': 'GABRB2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456360', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456365', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456370', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456375', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456380', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456385', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000113327', 'approvedSymbol': 'GABRG2', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma2', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456390', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456395', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456400', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456405', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456410', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456415', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000166206', 'approvedSymbol': 'GABRB3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit beta3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456420', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456425', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456430', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456435', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456440', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456445', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000109158', 'approvedSymbol': 'GABRA4', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit alpha4', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456450', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456455', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456460', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456465', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456470', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456475', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000182256', 'approvedSymbol': 'GABRG3', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit gamma3', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456480', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456485', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456490', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}, {'UUID': 'DrugTargetsIndication121923_text_456495', 'drugName': 'Cenobamate', 'tradeNames_list': "['Xcopri']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000268089', 'approvedSymbol': 'GABRQ', 'approvedName': 'gamma-aminobutyric acid type A receptor subunit theta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Focal-onset seizure'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1052 | Q16 | What Small molecule therapies have been approved by the FDA to treat eye infection? | There are no drug Small molecule therapies approved to treat eye infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eye infection" OR LOWER(mesh_heading) = "eye infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.321 | Q16 | What Small molecule therapies have been approved by the FDA to treat AIDS dementia? | There are no drug Small molecule therapies approved to treat AIDS dementia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aids dementia" OR LOWER(mesh_heading) = "aids dementia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.283 | Q16 | What Protein therapies have been approved by the FDA to treat retinal vasculitis? | There are no drug Protein therapies approved to treat retinal vasculitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinal vasculitis" OR LOWER(mesh_heading) = "retinal vasculitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1596 | Q16 | What Small molecule therapies have been approved by the FDA to treat salivary gland carcinoma? | There are no drug Small molecule therapies approved to treat salivary gland carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "salivary gland carcinoma" OR LOWER(mesh_heading) = "salivary gland carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1056 | Q16 | What Small molecule therapies have been approved by the FDA to treat fallopian tube cancer? | There are no drug Small molecule therapies approved to treat fallopian tube cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fallopian tube cancer" OR LOWER(mesh_heading) = "fallopian tube cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1368 | Q16 | What Small molecule therapies have been approved by the FDA to treat nephrotic syndrome? | There are 3 Small molecule therapy drugs that are approved to treat nephrotic syndrome which are as follows: Prednisone, Dexamethasone, and Spironolactone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nephrotic syndrome" OR LOWER(mesh_heading) = "nephrotic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217643', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_217851', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218059', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218267', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218475', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218683', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218891', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219099', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219307', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219515', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219723', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219931', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220139', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220347', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220555', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220763', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226624', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226909', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227194', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227479', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227764', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228049', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228619', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228904', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229189', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229474', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229759', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230044', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_232039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_232324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094355', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094393', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094431', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094469', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094507', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094545', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094583', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094621', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1094659', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.428 | Q16 | What Small molecule therapies have been approved by the FDA to treat Epstein-Barr virus infection? | There are no drug Small molecule therapies approved to treat Epstein-Barr virus infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epstein-barr virus infection" OR LOWER(mesh_heading) = "epstein-barr virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.557 | Q16 | What Small molecule therapies have been approved by the FDA to treat Myelofibrosis? | There are 2 Small molecule therapy drugs that are approved to treat Myelofibrosis which are as follows: Ruxolitinib Phosphate and Fedratinib Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myelofibrosis" OR LOWER(mesh_heading) = "myelofibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_843626', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843639', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843652', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843665', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843678', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843691', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843704', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843717', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843730', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843743', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843756', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843769', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843782', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843795', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843808', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843821', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843834', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843847', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843860', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843873', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843886', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843899', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843912', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843925', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843938', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843951', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843964', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843977', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843990', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844003', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844016', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844029', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844042', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844055', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844068', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844081', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844094', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844107', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844120', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844133', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844146', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844159', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844172', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844185', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844198', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844211', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844224', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844237', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844250', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844263', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844276', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844289', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844302', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844315', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844328', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844341', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844354', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844367', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844380', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844393', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844406', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844419', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844432', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844445', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844458', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844471', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844484', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844497', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844510', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844523', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844536', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844549', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844562', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844575', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844588', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844601', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844614', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844627', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844640', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844653', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844666', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844679', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844692', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844705', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844718', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844731', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844744', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844757', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844770', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844783', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844796', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844809', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844822', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844835', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844848', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844861', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844874', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844887', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844900', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844913', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.598 | Q16 | What Small molecule therapies have been approved by the FDA to treat Prader-Willi syndrome? | There are no drug Small molecule therapies approved to treat Prader-Willi syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prader-willi syndrome" OR LOWER(mesh_heading) = "prader-willi syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1727 | Q16 | What Small molecule therapies have been approved by the FDA to treat urethritis? | Lidocaine is the only Small molecule therapy approved by the FDA to treat urethritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urethritis" OR LOWER(mesh_heading) = "urethritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637783', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_637898', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638013', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638128', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638243', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638358', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638473', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638588', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638703', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638818', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_638933', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639048', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639163', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639278', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639393', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639508', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639623', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639738', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639853', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_639968', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640083', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640198', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640313', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640428', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640543', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640658', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640773', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_640888', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641003', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641118', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641233', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641348', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641463', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641578', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641693', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641808', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_641923', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642038', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642153', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642268', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642383', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642498', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642613', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642728', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642843', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_642958', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643073', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643188', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643303', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643418', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643533', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643648', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643763', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643878', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_643993', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_644108', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_644223', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_644338', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_644453', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}, {'UUID': 'DrugTargetsIndication121923_text_644568', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urethritis', 'efo_term': 'urethritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.371 | Q16 | What Small molecule therapies have been approved by the FDA to treat Bronchospasm? | There are 4 Small molecule therapy drugs that are approved to treat Bronchospasm which are as follows: Ipratropium Bromide, Tiotropium Bromide, Albuterol Sulfate, and Albuterol. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchospasm" OR LOWER(mesh_heading) = "bronchospasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857474', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857857', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857868', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857879', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857890', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857901', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857912', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857923', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857934', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857945', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857956', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857967', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857978', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_857989', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858000', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858011', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858022', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858033', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858044', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858055', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858066', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858077', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858088', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858099', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858110', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858121', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858132', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858143', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858154', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858165', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858176', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858187', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858198', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858209', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858220', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858231', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858242', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858253', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_858264', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000133019', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936201', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936210', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936219', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936228', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936237', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936246', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936255', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936264', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936273', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936282', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936291', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936300', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936309', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936318', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936327', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936336', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936345', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936354', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936363', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936372', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936381', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936390', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936399', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936408', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936417', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936426', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936435', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936444', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936453', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936462', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936471', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936480', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936489', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936498', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936507', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936516', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936525', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936534', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936543', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936552', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936561', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936570', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936579', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936588', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936617', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936646', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936675', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936704', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936733', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936762', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936791', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936820', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936849', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936878', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936907', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936936', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936965', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}, {'UUID': 'DrugTargetsIndication121923_text_936994', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1220 | Q16 | What Small molecule therapies have been approved by the FDA to treat inverted papilloma? | There are no drug Small molecule therapies approved to treat inverted papilloma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inverted papilloma" OR LOWER(mesh_heading) = "inverted papilloma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1378 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuroma? | There are no drug Small molecule therapies approved to treat neuroma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroma" OR LOWER(mesh_heading) = "neuroma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1098 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastritis? | There are no drug Small molecule therapies approved to treat gastritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastritis" OR LOWER(mesh_heading) = "gastritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1425 | Q16 | What Small molecule therapies have been approved by the FDA to treat osteosarcoma? | There are no drug Small molecule therapies approved to treat osteosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteosarcoma" OR LOWER(mesh_heading) = "osteosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.847 | Q16 | What Small molecule therapies have been approved by the FDA to treat breast ductal carcinoma in situ? | There are no drug Small molecule therapies approved to treat breast ductal carcinoma in situ. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast ductal carcinoma in situ" OR LOWER(mesh_heading) = "breast ductal carcinoma in situ") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.229 | Q16 | What Protein therapies have been approved by the FDA to treat myocardial infarction? | There are no drug Protein therapies approved to treat myocardial infarction. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myocardial infarction" OR LOWER(mesh_heading) = "myocardial infarction") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1689 | Q16 | What Small molecule therapies have been approved by the FDA to treat thrombophilia? | There are no drug Small molecule therapies approved to treat thrombophilia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombophilia" OR LOWER(mesh_heading) = "thrombophilia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1393 | Q16 | What Small molecule therapies have been approved by the FDA to treat obsessive-compulsive disorder? | There are no drug Small molecule therapies approved to treat obsessive-compulsive disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "obsessive-compulsive disorder" OR LOWER(mesh_heading) = "obsessive-compulsive disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1433 | Q16 | What Small molecule therapies have been approved by the FDA to treat ovarian sex cord-stromal tumor? | There are no drug Small molecule therapies approved to treat ovarian sex cord-stromal tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ovarian sex cord-stromal tumor" OR LOWER(mesh_heading) = "ovarian sex cord-stromal tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1356 | Q16 | What Small molecule therapies have been approved by the FDA to treat myofascial pain syndrome? | There are no drug Small molecule therapies approved to treat myofascial pain syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myofascial pain syndrome" OR LOWER(mesh_heading) = "myofascial pain syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.67 | Q16 | What Protein therapies have been approved by the FDA to treat T-Cell Prolymphocytic Leukemia? | There are no drug Protein therapies approved to treat T-Cell Prolymphocytic Leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "t-cell prolymphocytic leukemia" OR LOWER(mesh_heading) = "t-cell prolymphocytic leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.